Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

3.39USD
18 Jul 2018
Change (% chg)

$-0.06 (-1.74%)
Prev Close
$3.45
Open
$3.45
Day's High
$3.45
Day's Low
$3.19
Volume
8,551
Avg. Vol
19,240
52-wk High
$7.67
52-wk Low
$3.07

Latest Key Developments (Source: Significant Developments)

Therapix Announces Positive Data From Pre-Clinical Studies For Pain Treatment Drug
Tuesday, 17 Jul 2018 08:30am EDT 

July 17 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES POSITIVE DATA FROM RECENT PRE-CLINICAL STUDIES FOR ITS DRUG CANDIDATE THX-160 FOR TREATMENT OF PAIN.THERAPIX BIOSCIENCES LTD - IN PRECLINICAL STUDIES, THX-160 WAS WELL TOLERATED AND DID NOT CAUSE ANY SIGNIFICANT ADVERSE CLINICAL EFFECTS.THERAPIX BIOSCIENCES - EFFICACY STUDIES SHOWED ANALGESIC SUPERIORITY OF THX-160 OVER CONTROL, WERE COMPARABLE TO HIGH-DOSE MORPHINE ANALGESIC EFFECTS.  Full Article

Therapix Biosciences Signs Term Sheet For The Transfer Of Non-Pain Cannabinoid-Based Drug Pipeline Assets To Cure Pharmaceutical
Thursday, 12 Jul 2018 08:30am EDT 

July 12 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES SIGNS TERM SHEET FOR THE TRANSFER OF NON-PAIN CANNABINOID-BASED DRUG PIPELINE ASSETS TO CURE PHARMACEUTICAL.THERAPIX BIOSCIENCES LTD - PARTIES PROPOSE THAT THERAPIX WILL RECEIVE NEWLY ISSUED SHARES IN CURE IN EXCHANGE FOR ASSETS.THERAPIX BIOSCIENCES - PURSUANT TO TERM SHEET THERAPIX WILL BECOME SIGNIFICANT SHAREHOLDER IN CURE.THERAPIX BIOSCIENCES LTD - TERM SHEET CONTEMPLATES THERAPIX CEO & CHAIRMAN, ASCHER SCHMULEWITZ, WILL BE APPOINTED TO CURE'S BOARD.THERAPIX BIOSCIENCES LTD - RECEIPT OF ADDITIONAL FINANCING IS ONE OF CONDITIONS OF ACQUISITION, SOME OF WHICH MAY BE PROVIDED BY THERAPIX.  Full Article

Therapix Biosciences Ltd Files For Mixed Shelf Of Up To $50 Million
Wednesday, 20 Jun 2018 02:44pm EDT 

June 20 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES LTD FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING.  Full Article

Therapix Biosciences Reports Q1 Shr Loss $0.01
Thursday, 31 May 2018 04:55pm EDT 

May 31 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.01.THERAPIX BIOSCIENCES - CASH TOTALED $7.5 MILLION AS OF MARCH 31, 2018, COMPARED TO $9.2 MILLION AS OF DECEMBER 31, 2017.THERAPIX BIOSCIENCES - CO CURRENTLY BELIEVES THAT CASH BALANCE WILL BE SUFFICIENT TO MAINTAIN ITS CURRENT OPERATIONS INTO Q2 2019.  Full Article

Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain
Tuesday, 20 Mar 2018 10:13am EDT 

March 20 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN.THERAPIX BIOSCIENCES - EXPECTS TO COMMENCE PHASE IIA CLINICAL TRIAL FOR CHRONIC LOW BACK PAIN DRUG DURING Q2 2018.  Full Article

Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary
Tuesday, 9 Jan 2018 08:37am EST 

Jan 9 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018.THERAPIX BIOSCIENCES LTD - ‍EXPANDING INTO PRECISION MEDICINE THROUGH A NEW FULLY-OWNED SUBSIDIARY IN ORDER TO DEVELOP "NOVEL SOLUTIONS FOR PAIN"​.  Full Article

Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement
Tuesday, 26 Dec 2017 04:10pm EST 

Dec 26 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING.THERAPIX BIOSCIENCES SAYS IS IN THE PROCESS OF SEARCHING FOR A NEW CHIEF FINANCIAL OFFICER.  Full Article

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 08:30am EDT 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

Therapix biosciences says CEO Dr. Haber resigned
Wednesday, 24 May 2017 04:05pm EDT 

May 24 (Reuters) - Therapix Biosciences Ltd :Therapix biosciences announces ceo change.Says ceo dr haber resigned.Therapix biosciences ltd - board of directors is undertaking a search to identify a permanent, u.s. Based chief executive officer.  Full Article